• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by 180 Life Sciences Corp.

    8/12/25 1:00:24 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    180 Life Sciences Corp.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    68236V302

    (CUSIP Number)


    08/04/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68236V302


    1Names of Reporting Persons

    STEADFAST CAPITAL MANAGEMENT LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    11,320,754.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    11,320,754.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,320,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.3 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    68236V302


    1Names of Reporting Persons

    American Steadfast, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,109,434.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,109,434.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,109,434.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    68236V302


    1Names of Reporting Persons

    Steadfast International Master Fund Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,211,320.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,211,320.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,211,320.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    68236V302


    1Names of Reporting Persons

    Robert S. Pitts, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    11,320,754.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    11,320,754.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,320,754.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    180 Life Sciences Corp.
    (b)Address of issuer's principal executive offices:

    3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, 94306
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this statement on Schedule 13G (collectively, the "Reporting Persons") are: - Steadfast Capital Management LP, a Delaware limited partnership (the "Investment Manager"). - American Steadfast, L.P., a Delaware limited partnership ("American Steadfast"). - Steadfast International Master Fund Ltd., a Cayman Islands exempted company (the "Offshore Fund"). - Robert S. Pitts, Jr., a United States Citizen ("Mr. Pitts"). Mr. Pitts is the controlling principal of the Investment Manager. The Investment Manager has the power to vote and dispose of the securities held by American Steadfast and the Offshore Fund.
    (b)Address or principal business office or, if none, residence:

    The business address of each of Mr. Pitts, the Investment Manager and American Steadfast is 450 Park Avenue, 20th Floor, New York, New York 10022. The business address of the Offshore Fund is c/o Morgan Stanley Fund Services (Cayman) Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.
    (c)Citizenship:

    Each of the Investment Manager and American Steadfast is a limited partnership formed under the laws of the State of Delaware. The Offshore Fund is an exempted company formed under the laws of the Cayman Islands. Mr. Pitts is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    68236V302
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of August 4, 2025, the Reporting Persons beneficially owned an aggregate of 11,320,754 shares of the Issuer's Common Stock. Specifically: (i) The Investment Manager beneficially owned 11,320,754 shares of Common Stock. (ii) American Steadfast beneficially owned 4,109,434 shares of Common Stock. (iii) The Offshore Fund beneficially owned 7,211,320 shares of Common Stock. (iv) Mr. Pitts beneficially owned 11,320,754 shares of Common Stock. (v) Collectively, the Reporting Persons beneficially owned 11,320,754 shares of Common Stock.
    (b)Percent of class:

    As of August 4, 2025, the Reporting Persons may be deemed to have beneficially owned 11,320,754 shares of Common Stock or 7.3% of the Issuer's Common Stock outstanding, which percentage was calculated based on 154,032,084 shares of Common Stock outstanding as of August 4, 2025, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 5, 2025. Specifically: (i) The Investment Manager's beneficial ownership of 11,320,754 shares of Common Stock represented 7.3% of the outstanding Common Stock. (ii) American Steadfast's beneficial ownership of 4,109,434 shares of Common Stock represented 2.7% of the outstanding Common Stock. (iii) The Offshore Fund's beneficial ownership of 7,211,320 shares of Common Stock represented 4.7% of the outstanding Common Stock. (iv) Mr. Pitts' beneficial ownership of 11,320,754 shares of Common Stock represented 7.3% of the outstanding Common Stock. (v) Collectively, the Reporting Persons' beneficial ownership of 11,320,754 shares of Common Stock represented 7.3% of the outstanding Common Stock.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Not Applicable

     (ii) Shared power to vote or to direct the vote:

    American Steadfast had shared power with the Investment Manager and Mr. Pitts to vote or direct the vote of the 4,109,434 shares of Common Stock beneficially owned by American Steadfast. The Offshore Fund had shared power with the Investment Manager and Mr. Pitts to vote or direct the vote of the 7,211,320 shares of Common Stock beneficially owned by the Offshore Fund.

     (iii) Sole power to dispose or to direct the disposition of:

    Not Applicable

     (iv) Shared power to dispose or to direct the disposition of:

    American Steadfast had shared power with the Investment Manager and Mr. Pitts to dispose or direct the disposition of the 4,109,434 shares of Common Stock beneficially owned by American Steadfast. The Offshore Fund had shared power with the Investment Manager and Mr. Pitts to dispose or direct the disposition of the 7,211,320 shares of Common Stock beneficially owned by the Offshore Fund.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STEADFAST CAPITAL MANAGEMENT LP
     
    Signature:/s/ Sheena Koshy
    Name/Title:Sheena Koshy/Chief Operating Officer
    Date:08/12/2025
     
    American Steadfast, L.P.
     
    Signature:/s/ Sheena Koshy
    Name/Title:Sheena Koshy/Chief Operating Officer of Steadfast Capital Management LP, Attorney-in-Fact
    Date:08/12/2025
     
    Steadfast International Master Fund Ltd.
     
    Signature:/s/ Sheena Koshy
    Name/Title:Director
    Date:08/12/2025
     
    Robert S. Pitts, Jr.
     
    Signature:/s/ Robert S. Pitts, Jr
    Name/Title:Robert S. Pitts, Jr.
    Date:08/12/2025
    Exhibit Information

    Exhibit A - Joint Filing Agreement Exhibit B

    Get the next $ATNF alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Heter Crystal Jane

    3 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 4:15:12 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    SEC Filings

    View All

    180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/20/25 7:30:26 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: 180 Life Sciences Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K/A - ETHZilla Corp (0001690080) (Filer)

    8/20/25 7:32:28 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by 180 Life Sciences Corp.

    SCHEDULE 13D/A - ETHZilla Corp (0001690080) (Subject)

    8/18/25 5:22:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and

    8/12/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif., Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025. The Company intends to us

    8/11/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

    12/12/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

    12/4/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    10/18/24 5:00:02 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    2/14/24 3:27:19 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care